Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Gore

Showing results (91-100 of 215) with videos related to

Pageof 22
Sort By:
Cancer|February 26, 2016
Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national databaseSean A Fletcher, Angel M Cronin, Amer M Zeidan, et al.
Blood Reviews|November 20, 2020
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolvedRory M Shallis, Robert P Gale, Hillard M Lazarus, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 8, 2019
Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's LymphomaScott F Huntington, Jessica R Hoag, Rong Wang, et al.
Leukemia & Lymphoma|December 28, 2019
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study<sup>†</sup>Amy J Davidoff, Xin Hu, Jan Philipp Bewersdorf, et al.
Cancer|June 17, 2017
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based studyAmer M Zeidan, Xin Hu, Jessica B Long, et al.
Leukemia & Lymphoma|August 26, 2016
Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United StatesAmer M Zeidan, Rong Wang, Cary P Gross, et al.
SLAS Discovery : Advancing Life Sciences R & D|October 23, 2025
High-throughput combination screening of Pidnarulex and other G-quadruplex ligands in multi-cell type tumor spheroidsThomas S Dexheimer, Nathan P Coussens, Thomas Silvers, et al.
The Journal of Biological Chemistry|September 10, 2003
Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitroXue Wei Meng, Joya Chandra, David Loegering, et al.
Leukemia & Lymphoma|June 8, 2019
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysisAmer M Zeidan, Weiwei Zhu, Maximilian Stahl, et al.
Biomedical Chromatography : BMC|June 9, 2025
Quantitation of Tuvusertib (M1774) in Human Plasma by LC-MS/MSTien V Le, Robert A Parise, Julianne L Holleran, et al.
Pageof 22

Showing results (91-100 of 215) with videos related to

Sort By:
Pageof 22
Cancer|February 26, 2016
Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national databaseSean A Fletcher, Angel M Cronin, Amer M Zeidan, et al.
Blood Reviews|November 20, 2020
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolvedRory M Shallis, Robert P Gale, Hillard M Lazarus, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 8, 2019
Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's LymphomaScott F Huntington, Jessica R Hoag, Rong Wang, et al.
Leukemia & Lymphoma|December 28, 2019
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study<sup>†</sup>Amy J Davidoff, Xin Hu, Jan Philipp Bewersdorf, et al.
Cancer|June 17, 2017
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based studyAmer M Zeidan, Xin Hu, Jessica B Long, et al.
Leukemia & Lymphoma|August 26, 2016
Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United StatesAmer M Zeidan, Rong Wang, Cary P Gross, et al.
SLAS Discovery : Advancing Life Sciences R & D|October 23, 2025
High-throughput combination screening of Pidnarulex and other G-quadruplex ligands in multi-cell type tumor spheroidsThomas S Dexheimer, Nathan P Coussens, Thomas Silvers, et al.
The Journal of Biological Chemistry|September 10, 2003
Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitroXue Wei Meng, Joya Chandra, David Loegering, et al.
Leukemia & Lymphoma|June 8, 2019
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysisAmer M Zeidan, Weiwei Zhu, Maximilian Stahl, et al.
Biomedical Chromatography : BMC|June 9, 2025
Quantitation of Tuvusertib (M1774) in Human Plasma by LC-MS/MSTien V Le, Robert A Parise, Julianne L Holleran, et al.
Pageof 22